GEARING UP FOR WWJ 950'S THAW RADIOTHON: BID IN THE ONLINE AUCTION NOW!  

Phase 2 Clinical Study

Esperion Therapeutics Presents Promising Test Results On Cholesterol DrugThe pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today's cholesterol-lowering statin drugs.

More From CBS Detroit

Daily J
Valenti and Foster

Watch & Listen